Rituximab is effective for steroid-refractory sclerodermatous chronic graft-versus-host disease
- 20 October 2005
- journal article
- Published by Springer Nature in Leukemia
- Vol. 20 (1) , 172-173
- https://doi.org/10.1038/sj.leu.2403996
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Anti-CD20 monoclonal antibody treatment in 6 patients with therapy-refractory chronic graft-versus-host diseaseBlood, 2004
- Chronic graft-versus-host disease: where do we go from here?Bone Marrow Transplantation, 2004
- Influence of extracorporeal photopheresis on clinical and laboratory parameters in chronic graft-versus-host disease and analysis of predictors of responseBlood, 2003
- Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibodyTransplantation and Cellular Therapy, 2003
- Variable patterns of response to rituximab treatment in adults with chronic idiopathic thrombocytopenic purpuraBlood, 2002
- Anti-CD20 Chimeric Monoclonal Antibody Treatment of Refractory Immune-Mediated Thrombocytopenia in a Patient with Chronic Graft-versus-Host DiseaseAnnals of Internal Medicine, 2000
- SERUM TRANSFORMING GROWTH FACTOR-??1 LEVELS IN BONE MARROW TRANSPLANT RECIPIENTS CORRELATE WITH BLOOD CELL COUNTS AND CHRONIC GRAFT-VERSUS-HOST DISEASE1Transplantation, 1999
- AUTOIMMUNITY AFTER ALLOGENEIC BONE MARROW TRANSPLANTATION A STUDY OF 53 LONG-TERM-SURVIVING PATIENTSTransplantation, 1988